Changes over the years in radiopharmaceutical design

Area of Science:

• Nuclear medicine
• Radiopharmaceutical chemistry
• Medical imaging

Background:

• Radiopharmaceuticals are vital for patient diagnosis and therapy, necessitating a multidisciplinary approach.
• Current radiotracer design often prioritizes radiochemistry over clinical needs, as exemplified by technetium-99m chelates used in over 70% of studies.
• Unmet clinical needs drive the development of novel radiotracers for various diseases.

Purpose of the Study:

• To explore the development criteria for radiopharmaceuticals, balancing radiochemistry, imaging compatibility, and pharmaceutical relevance.
• To highlight advancements in targeted radiotracers for neurologic, psychiatric, inflammatory, cardiovascular, and oncologic applications.
• To discuss the evolution of imaging techniques like SPECT/CT and PET in enhancing diagnostic specificity and therapeutic applications.

Main Methods:

• Review of radiopharmaceutical design principles and their clinical application.
• Analysis of targeted radiotracer development for specific disease areas.
• Evaluation of advancements in diagnostic and therapeutic radionuclide applications, including theragnostic agents.

Main Results:

• Technetium-99m chelates, despite not being based on clinical need, remain widely used.
• Targeted radiotracers show promise in assessing disease progression and treatment response.
• SPECT/CT enhances SPECT imaging specificity, complementing cost-effective imaging solutions.

Conclusions:

• The development of effective radiopharmaceuticals requires collaboration between physicians, chemists, and imaging specialists.
• Theragnostic agents represent a significant advancement, particularly in oncology.
• Personalized medicine can be advanced through the continued search for optimal radiopharmaceuticals tailored to individual patients.